dishevelled segment polarity protein 2Genealiases: []
Q-omics provides the consensus-scored DVL2 profile across patient tissues and cancer cell-line models. DVL2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DVL2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, DVL2 protein abundance shows 21,722 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where DVL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DVL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DVL2 survival associations across molecular data types. DVL2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DVL2 RNA expression–survival associations across cancer types. High DVL2 expression shows unfavorable associations in MESO, KICH, LIHC and LUAD, but favorable associations in SCLC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for DVL2 RNA expression.
This table summarizes DVL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DVL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DVL2 shows higher tumor expression in HNSC, KIRP, KIRC, LIHC, COAD and LUSC. The HNSC box plot shows higher DVL2 RNA expression in tumor versus normal tissue (log2 FC = +1.151, t-test p < 0.001).
This table shows molecular features associated with DVL2 in patient tissues and cancer cell lines. In patient samples, DVL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DVL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
